Plunkett Research Online: Pharvaris NV

PHARVARIS NV (PHVS:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications......



Pharvaris NV
Ticker: PHVS
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 31 712036410
Fax:
Address: Emmy Noetherweg 2
Leiden, 2333 BK Netherlands

Map
Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
Contacts Description
Berndt ModigCEO/Co-Founder/Director
Anna NijdamChief Accounting Officer/Other Corporate Officer
See More
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications......See More See More

Auditor: PricewaterhouseCoopers Accountants N.V.
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (EUR)Bonus (EUR)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: